Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial (Co-ALS)

Project

Overview

Contributors

POLETTI ANGELO   Scientific Manager  

Departments involved

Type

AL_RIC - Bandi da altri enti di ricerca

Funder

AGENZIA ITALIANA DEL FARMACO - AIFA
External Organization Funding Organization

Date/time interval

September 19, 2018 - September 18, 2020

Project duration

24 months

Research Areas

Concepts


Settore BIO/13 - Biologia Applicata

Publications

Outputs (5)

Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial 
BRAIN COMMUNICATIONS
OXFORD UNIVERSITY PRESS
2024
Academic Article
Open Access
Altmetric is disabled. Enable it on "Use of Cookies"
Lysosomes Dysfunction Causes Mitophagy Impairment in PBMCs of Sporadic ALS Patients 
CELLS
MDPI
2022
Academic Article
Open Access
Altmetric is disabled. Enable it on "Use of Cookies"
Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggressive disease phenotype 
NEUROLOGICAL SCIENCES
SPRINGER-VERLAG ITALIA S.R.L.
2022
Academic Article
Reserved Access
Altmetric is disabled. Enable it on "Use of Cookies"
RNA molecular signature profiling in PBMCs of sporadic ALS patients: HSP70 overexpression is associated with nuclear SOD1 
CELLS
MDPI
2022
Academic Article
Open Access
Altmetric is disabled. Enable it on "Use of Cookies"